MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Intra-Cellular Therapies Inc

Închisă

SectorSănătate

131.89 -0.02

Rezumat

Modificarea prețului

24h

Curent

Minim

131.89

Maxim

131.89

Indicatori cheie

By Trading Economics

Venit

9.4M

-17M

Vânzări

24M

199M

EPS

-0.16

Marjă de profit

-8.475

Angajați

860

EBITDA

9.8M

-29M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-0.79% downside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.8B

14B

Deschiderea anterioară

131.91

Închiderea anterioară

131.89

Sentimentul știrilor

By Acuity

51%

49%

320 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Intra-Cellular Therapies Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 ian. 2025, 12:11 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 ian. 2025, 11:40 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22 ian. 2025, 14:09 UTC

Top știri
Câștiguri

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 ian. 2025, 11:22 UTC

Top știri
Câștiguri

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13 ian. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 ian. 2025, 20:12 UTC

Top știri
Achiziții, Fuziuni, Preluări

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 ian. 2025, 16:18 UTC

Top știri
Achiziții, Fuziuni, Preluări

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 ian. 2025, 15:57 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 ian. 2025, 14:10 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 ian. 2025, 12:25 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ian. 2025, 11:57 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ian. 2025, 11:56 UTC

Top știri
Achiziții, Fuziuni, Preluări

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 ian. 2025, 11:45 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 ian. 2025, 11:43 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 ian. 2025, 11:43 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 ian. 2025, 11:42 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 ian. 2025, 11:41 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 ian. 2025, 11:40 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 ian. 2025, 11:34 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 ian. 2025, 11:32 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 ian. 2025, 11:32 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 ian. 2025, 11:31 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 ian. 2025, 11:31 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 ian. 2025, 11:30 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 ian. 2025, 10:55 UTC

Achiziții, Fuziuni, Preluări

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 ian. 2025, 10:41 UTC

Achiziții, Fuziuni, Preluări

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Comparație

Modificare preț

Intra-Cellular Therapies Inc Așteptări

Obiectiv de preț

By TipRanks

-0.79% jos

Prognoză pe 12 luni

Medie 130.83 USD  -0.79%

Maxim 132 USD

Minim 118 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIntra-Cellular Therapies Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

4

Cumpărare

9

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

131.45 / 131.87Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

No Evidence

Termen lung

No Evidence

Sentiment

By Acuity

320 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.